Pharmacological management of Kaposi's sarcoma

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 11, 2011, Pages 1669-1690

  Sgadari, Cecilia ^a   Bacigalupo, Ilaria ^a   Barillari, Giovanni ^a,b   Ensoli, Barbara ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Clinical trials; Conventional treatment; Kaposi's sarcoma; Pathogenetic targeted therapies

Indexed keywords

ALITRETINOIN; ANTHRACYCLINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BEVACIZUMAB; BLEOMYCIN; CIDOFOVIR; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; GEMCITABINE; INCYCLINIDE; IRINOTECAN; ISOTRETINOIN; OGLUFANIDE; PACLITAXEL; PENTOSAN POLYSULFATE; RAPAMYCIN; REBIMASTAT; RECOMBINANT ALPHA INTERFERON; RETINOIC ACID; SEMAXANIB; SORAFENIB; SUNITINIB; TECOGALAN; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONFUSION; CRYOTHERAPY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; FLU LIKE SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LASER SURGERY; LIVER TOXICITY; LOCAL THERAPY; MYOSITIS; NEUROPATHY; NEUTROPENIA; PATHOGENESIS; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; SARCOMA, KAPOSI;

EID: 79960215216     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.577066     Document Type: Review

References (186)

1. Ensoli B, Sgadari C, Barillari G, et al. Biology of Kaposis sarcoma. Eur J Cancer 2001;37:1251-69
2. Phipps W, Ssewankambo F, Nguyen H, et al. Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda. PLoS One 2010;5:e13936
3. Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006;19:14-19 (Pubitemid 43032434)
4. Parkin DM, Sitas F, Chirenje M, et al. Part I: cancer in indigenous Africans - burden, distribution, and trends. Lancet Oncol 2008;9:683-92 (Pubitemid 351878054)
5. Mosam A, Aboobaker J, Shaik F. Kaposis sarcoma in sub-Saharan Africa: a current perspective. Curr Opin Infect Dis 2010;23:119-23
6. Pantanowitz L, Otis CN, Dezube BJ. Immunohistochemistry in Kaposis sarcoma. Clin Exp Dermatol 2010;35:68-72
7. Pyakurel P, Pak F, Mwakigonja AR, et al. Lymphatic and vascular origin of Kaposis sarcoma spindle cells during tumor development. Int J Cancer 2006;119:1262-7 (Pubitemid 44258798)
8. Jussila L, Valtola R, Partanen TA, et al. Lymphatic endothelium and Kaposis sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res 1998;58:1599-604 (Pubitemid 28215077)
9. Hong YK, Foreman K, Shin JW, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 2004;36:683-5 (Pubitemid 38886627)
10. Browning PJ, Sechler JM, Kaplan M, et al. Identification and culture of Kaposis sarcoma-like spindle cells from the peripheral blood of human immunodeficiency virus-1-infected individuals and normal controls. Blood 1994;84:2711-20 (Pubitemid 24317404)
11. Monini P, Colombini S, Sturzl M, et al. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposis sarcoma. Blood 1999;93:4044-58 (Pubitemid 29279246)
12. Sirianni MC, Uccini S, Angeloni A, et al. Circulating spindle cells: correlation with human herpesvirus-8 (HHV-8) infection and Kaposis sarcoma. Lancet 1997;349:255 (Pubitemid 27051000)
13. Mesri EA, Cesarman E, Boshoff C. Kaposis sarcoma and its associated herpesvirus. Nat Rev Cancer 2010;10:707-19
14. Ensoli B, Nakamura S, Salahuddin SZ, et al. AIDS-Kaposis sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 1989;243:223-6 (Pubitemid 19035359)
15. Salahuddin SZ, Nakamura S, Biberfeld P, et al. Angiogenic properties of Kaposis sarcoma-derived cells after long-term culture in vitro. Science 1988;242:430-3
16. Aboulafia D, Miles SA, Saks SR, et al. Intravenous recombinant tumor necrosis factor in the treatment of AIDS-related Kaposis sarcoma. J Acquir Immune Defic Syndr 1989;2:54-8 (Pubitemid 19127075)
17. Krigel RL, Padavic-Shaller KA, Rudolph AR, et al. Exacerbation of epidemic Kaposis sarcoma with a combination of interleukin-2 and betainterferon: results of a phase 2 study. J Biol Response Mod 1989;8:359-65 (Pubitemid 19183887)
18. Maral T. The Koebner phenomenon in immunosuppression-related Kaposis sarcoma. Ann Plast Surg 2000;44:646-8 (Pubitemid 30397259)
19. Webster-Cyriaque J. Development of Kaposis sarcoma in a surgical wound. N Engl J Med 2002;346:1207-10 (Pubitemid 34984582)
20. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposis sarcoma. J Clin Oncol 2005;23:5224-8 (Pubitemid 46224033)
21. Samaniego F, Markham PD, Gendelman R, et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposis sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 1998;152:1433-43 (Pubitemid 28275002)
22. Gill PS, Tsai YC, Rao AP, et al. Evidence for multiclonality in multicentric Kaposis sarcoma. Proc Natl Acad Sci U S A 1998;95:8257-61 (Pubitemid 28326100)
23. Rabkin CS, Janz S, Lash A, et al. Monoclonal origin of multicentric Kaposis sarcoma lesions. N Engl J Med 1997;336:988-93 (Pubitemid 27152784)
24. Toschi E, Barillari G, Sgadari C, et al. Activation of matrix-metalloproteinase-2 and membrane-type-1-matrixmetalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol Biol Cell 2001;12:2934-46 (Pubitemid 33062952)
25. Barillari G, Ensoli B. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposis sarcoma. Clin Microbiol Rev 2002;15:310-26 (Pubitemid 34303768)
26. Ensoli B, Sturzl M, Monini P. Reactivation and role of HHV-8 in Kaposis sarcoma initiation. Adv Cancer Res 2001;81:161-200 (Pubitemid 32566016)
27. Sturzl M, Zietz C, Monini P, et al. Human herpesvirus-8 and Kaposis sarcoma: relationship with the multistep concept of tumorigenesis. Adv Cancer Res 2001;81:125-59 (Pubitemid 32566015)
28. Boshoff C, Schulz TF, Kennedy MM, et al. Kaposis sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med 1995;1:1274-8
29. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposis sarcoma. Science 1994;266:1865-9
30. Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposis sarcoma. Nat Med 1996;2:925-11
31. Kedes DH, Operskalski E, Busch M, et al. The seroepidemiology of human herpesvirus 8 (Kaposis sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med 1996;2:918-24 (Pubitemid 26296764)
32. Staskus KA, Zhong W, Gebhard K, et al. Kaposis sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 1997;71:715-19 (Pubitemid 26412345)
33. Renne R, Zhong W, Herndier B, et al. Lytic growth of Kaposis sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 1996;2:342-6 (Pubitemid 26080656)
34. Chang Y, Moore PS, Talbot SJ, et al. Cyclin encoded by KS herpesvirus. Nature 1996;382:410
35. Sarid R, Sato T, Bohenzky RA, et al. Kaposis sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 1997;3:293-8 (Pubitemid 27112926)
36. Arvanitakis L, Geras-Raaka E, Varma A, et al. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997;385:347-50
37. Sturzl M, Hohenadl C, Zietz C, et al. Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposis sarcoma spindle cells. J Natl Cancer Inst 1999;91:1725-33 (Pubitemid 29518767)
38. Gao SJ, Boshoff C, Jayachandra S, et al. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 1997;15:1979-85 (Pubitemid 27480686)
39. Ensoli B, Barillari G, Salahuddin SZ, et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposis sarcoma lesions of AIDS patients. Nature 1990;345:84-6
40. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposis sarcoma. Nature 1994;371:674-80 (Pubitemid 24327325)
41. Lebbe C, Legendre C, Frances C. Kaposi sarcoma in transplantation. Transplant Rev (Orlando) 2008;4:252-61
42. Brenner B, Rakowsky E, Katz A, et al. Tailoring treatment for classical Kaposis sarcoma: comprehensive clinical guidelines. Int J Oncol 1999;14:1097-102
43. Tur E, Brenner S. Treatment of Kaposis sarcoma. Arch Dermatol 1996;132:327-31
44. Chun YS, Chang SN, Park WH. A case of classical Kaposis sarcoma of the penis showing a good response to high-energy pulsed carbon dioxide laser therapy. J Dermatol 1999;26:240-3 (Pubitemid 29219967)
45. Marchell N, Alster TS. Successful treatment of cutaneous Kaposis sarcoma by the 585-nm pulsed dye laser. Dermatol Surg 1997;23:973-5 (Pubitemid 27476118)
46. Zouboulis CC. Cryosurgery in dermatology. Eur J Dermatol 1998;8:466-74 (Pubitemid 28474139)
47. Lo TC, Salzman FA, Smedal MI, et al. Radiotherapy for Kaposis sarcoma. Cancer 1980;45:684-7
48. Hauerstock D, Gerstein W, Vuong T. Results of radiation therapy for treatment of classic Kaposi sarcoma. J Cutan Med Surg 2009;13:18-21
49. Gressen EL, Rosenstock JG, Xie Y, et al. Palliative treatment of epidemic Kaposi sarcoma of the feet. Am J Clin Oncol 1999;22:286-90 (Pubitemid 30263324)
50. Epstein JB. Treatment of oral Kaposi sarcoma with intralesional vinblastine. Cancer 1993;71:1722-5 (Pubitemid 23067385)
51. Klein E, Schwartz RA, Laor Y, et al. Treatment of Kaposis sarcoma with vinblastine. Cancer 1980;45:427-31
52. Brambilla L, Bellinvia M, Tourlaki A, et al. Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. Br J Dermatol 2010;162:854-9
53. Poignonec S, Lachiver LD, Lamas G, et al. Intralesional bleomycin for acquired immunodeficiency syndrome-associated cutaneous Kaposis sarcoma. Arch Dermatol 1995;131:228
54. Altucci L, Leibowitz MD, Ogilvie KM, et al. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007;6:793-810 (Pubitemid 47504871)
55. Komi Y, Sogabe Y, Ishibashi N, et al. Acyclic retinoid inhibits angiogenesis by suppressing the MAPK pathway. Lab Invest 2010;90:52-60
56. Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous Kaposis sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. J Acquir Immune Defic Syndr 1999;22:235-46 (Pubitemid 30012667)
57. Bodsworth NJ, Bloch M, Bower M, et al. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposis sarcoma. Am J Clin Dermatol 2001;2:77-87 (Pubitemid 32592524)
58. Morganroth GS. Topical 0.1% alitretinoin gel for classic Kaposi sarcoma. Arch Dermatol 2002;138:542-3 (Pubitemid 34290043)
59. Rongioletti F, Zaccaria E, Viglizzo G. Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma: first European experience. Br J Dermatol 2006;155:856-7 (Pubitemid 44352581)
60. Gill PS, Lunardi-Ishkandar Y, Louie S, et al. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposis sarcoma. N Engl J Med 1996;335:1261-9 (Pubitemid 26349267)
61. Tavio M, Nasti G, Simonelli C, et al. Human chorionic gonadotropin in the treatment of HIV-related Kaposis sarcoma. Eur J Cancer 1998;34:1634-7 (Pubitemid 28446351)
62. Darzynkiewicz Z. The butler did it: search for killer(s) of Kaposis sarcoma cells in preparations of human chorionic gonadotropin. J Natl Cancer Inst 1999;91:104-6 (Pubitemid 29042687)
63. Trattner A, Reizis Z, David M, et al. The therapeutic effect of intralesional interferon in classical Kaposis sarcoma. Br J Dermatol 1993;129:590-3 (Pubitemid 23336458)
64. Qureshi YA, Karp CL, Dubovy SR. Intralesional interferon alpha-2b therapy for adnexal Kaposi sarcoma. Cornea 2009;28:941-3
65. Dupuy J, Price M, Lynch G, et al. Intralesional interferon-alpha and zidovudine in epidemic Kaposis sarcoma. J Am Acad Dermatol 1993;28:966-72 (Pubitemid 23160650)
66. Bilu D, Sauder DN. Imiquimod: modes of action. Br J Dermatol 2003;149(Suppl 66):5-8 (Pubitemid 38064505)
67. Li VW, Li WW, Talcott KE, et al. Imiquimod as an antiangiogenic agent. J Drugs Dermatol 2005;4:708-17
68. Celestin Schartz NE, Chevret S, Paz C, et al. Imiquimod 5% cream for treatment of HIV-negative Kaposis sarcoma skin lesions: a phase I to II, open-label trial in 17 patients. J Am Acad Dermatol 2008;58:585-91
69. Babel N, Eibl N, Ulrich C, et al. Development of Kaposis sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transpl Infect Dis 2008;10:59-62 (Pubitemid 351171313)
70. Rosen T. Limited extent AIDS-related cutaneous Kaposis sarcoma responsive to imiquimod 5% cream. Int J Dermatol 2006;45:854-6 (Pubitemid 43984397)
71. Elkin M, Miao HQ, Nagler A, et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J 2000;14:2477-85
72. Koon HB, Fingleton B, Lee JY, et al. Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr 2011;56:64-8
73. Nouri-Shirazi M, Guinet E. Evidence for the immunosuppressive role of nicotine on human dendritic cell functions. Immunology 2003;109:365-73 (Pubitemid 36783262)
74. Goedert JJ, Scoppio BM, Pfeiffer R, et al. Treatment of classic Kaposi sarcoma with a nicotine dermal patch: a phase II clinical trial. J Eur Acad Dermatol Venereol 2008;22:1101-9
75. Balasubramanian L, Evens AM. Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol 2006;18:354-9 (Pubitemid 44297246)
76. Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005;44:111-15
77. Volberding PA, Abrams DI, Conant M, et al. Vinblastine therapy for Kaposis sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:335-8 (Pubitemid 16238000)
78. Mintzer DM, Real FX, Jovino L, et al. Treatment of Kaposis sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1985;102:200-2 (Pubitemid 15157170)
79. Nasti G, Errante D, Talamini R, et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposis sarcoma: results of a phase II study. J Clin Oncol 2000;18:1550-7 (Pubitemid 30205402)
80. Lassoued K, Clauvel JP, Katlama C, et al. Treatment of the acquired immune deficiency syndrome-related Kaposis sarcoma with bleomycin as a single agent. Cancer 1990;66:1869-72 (Pubitemid 20385953)
81. RemicK SC, Reddy M, Herman D, et al. Continuous infusion bleomycin in AIDS-related Kaposis sarcoma. J Clin Oncol 1994;12:1130-6 (Pubitemid 24173925)
82. Sprinz E, Caldas AP, Mans DR, et al. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. Am J Clin Oncol 2001;24:177-84 (Pubitemid 32328001)
83. Brambilla L, Labianca R, Boneschi V, et al. Mediterranean Kaposis sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine. Cancer 1994;74:2873-28
84. Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposis sarcoma. Eur J Cancer 2001;37:1288-95
85. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposis sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002;2:281-92 (Pubitemid 34464739)
86. Brambilla L, Tourlaki A, Ferrucci S, et al. Treatment of classic Kaposis sarcoma-associated lymphedema with elastic stockings. J Dermatol 2006;33:451-6 (Pubitemid 43979227)
87. Brambilla L, Labianca R, Ferrucci SM, et al. Treatment of classical Kaposis sarcoma with gemcitabine. Dermatology 2001;202:119-22 (Pubitemid 32337161)
88. Strother RM, Gregory KM, Pastakia SD, et al. Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated Kaposis sarcoma in western Kenya. Oncology 2010;78:5-11
89. Vaccher E, di Gennaro G, Simonelli C, et al. Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposis sarcoma. AIDS 2005;19:1915-16 (Pubitemid 41546613)
90. Corona G, Vaccher E, Sandron S, et al. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposis sarcoma. Clin Pharmacol Ther 2008;83:601-6 (Pubitemid 351417055)
91. Hernandez DE, Pellino ML, Ramirez B. Acute myelocytic leukaemia associated with Kaposis sarcoma in a patient without serum antibodies to human immunodeficiency virus type 1. Br J Dermatol 1996;134:551-3 (Pubitemid 26090952)
92. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposis sarcoma. J Clin Pharmacol 1996;36:55-63 (Pubitemid 26058811)
93. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposis sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-51 (Pubitemid 28309039)
94. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposis sarcoma. J Clin Oncol 1998;16:683-91 (Pubitemid 28135616)
95. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposis sarcoma. J Clin Oncol 1996;14:2353-64 (Pubitemid 26264888)
96. Tulpule A, Yung RC, Wernz J, et al. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposis sarcoma. J Clin Oncol 1998;16:3369-74 (Pubitemid 28481634)
97. Cooley T, Henry D, Tonda M, et al. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposis sarcoma. Oncologist 2007;12:114-23 (Pubitemid 46143509)
98. Di Lorenzo G, Di Trolio R, Montesarchio V, et al. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. Cancer 2008;112:1147-52 (Pubitemid 351304601)
99. Sgadari C, Toschi E, Palladino C, et al. Mechanism of paclitaxel activity in Kaposis sarcoma. J Immunol 2000;165:509-17 (Pubitemid 30429545)
100. Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 2002;95:147-54 (Pubitemid 34743493)
101. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposis sarcoma. J Clin Oncol 1998;16:1112-21 (Pubitemid 28108748)
102. Cianfrocca M, Lee S, Von RJ, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010;116:3969-77
103. Brambilla L, Romanelli A, Bellinvia M, et al. Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases. Br J Dermatol 2008;158:1339-44 (Pubitemid 351692862)
104. Chao SC, Lee JY, Tsao CJ. Treatment of classical type Kaposis sarcoma with paclitaxel. Anticancer Res 2001;21:571-3
105. Patel N, Salifu M, Sumrani N, et al. Successful treatment of post-renal transplant Kaposis sarcoma with paclitaxel. Am J Transplant 2002;2:877-9 (Pubitemid 36306844)
106. Fardet L, Stoebner PE, Bachelez H, et al. Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection. Cancer 2006;106:1785-9
107. Lim ST, Tupule A, Espina BM, et al. Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2005;103:417-21 (Pubitemid 40129303)
108. Krown SE. Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 2001;13:374-81 (Pubitemid 32783416)
109. Ho DD, Hartshorn KL, Rota TR, et al. Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet 1985;1:602-4 (Pubitemid 15133883)
110. Chang J, Renne R, Dittmer D, et al. Inflammatory cytokines and the reactivation of Kaposis sarcoma-associated herpesvirus lytic replication. Virology 2000;266:17-25 (Pubitemid 30048632)
111. Monini P, Carlini F, Sturzl M, et al. Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells. J Virol 1999;73:4029-41 (Pubitemid 29189848)
112. Reiter Z, Ozes ON, Blatt LM, et al. A possible role for interferon-alpha and activated natural killer cells in remission of AIDS-related Kaposis sarcoma: in vitro studies. J Acquir Immune Defic Syndr 1992;5:469-76
113. Lebbe C, de Cremoux P, Millot G, et al. Characterization of in vitro culture of HIV-negative Kaposis sarcoma-derived cells. In vitro responses to alfa interferon. Arch Dermatol Res 1997;289:421-8 (Pubitemid 27331337)
114. Singh RK, Gutman M, Bucana CD, et al. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 1995;92:4562-6
115. Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998;58:808-14 (Pubitemid 28099496)
116. Magnone M, Holley JL, Shapiro R, et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995;59:1068-70
117. Krown SE. AIDS-associated Kaposis sarcoma: is there still a role for interferon alfa? Cytokine Growth Factor Rev 2007;18:395-402 (Pubitemid 47302825)
118. Krown SE, Li P, von Roenn JH, et al. Efficacy of low-dose interferon with antiretroviral therapy in Kaposis sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res 2002;22:295-303 (Pubitemid 34499710)
119. Krown SE, Lee JY, Lin L, et al. Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial. J Acquir Immune Defic Syndr 2006;41:149-53
120. van der Ende M, Mulder JW, van den Berge M, et al. Complete clinical and virological remission of refractory HIV-related Kaposis sarcoma with pegylated interferon alpha. AIDS 2007;21:1661-2 (Pubitemid 47075496)
121. Rustgi VK. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin 2009;25:991-1002
122. Tur E, Brenner S. Classic Kaposis sarcoma: low-dose interferon alfa treatment. Dermatology 1998;197:37-42 (Pubitemid 28327835)
123. Costa da Cunha CS, Lebbe C, Rybojad M, et al. Long-term follow-up of non-HIV Kaposis sarcoma treated with low-dose recombinant interferon alfa-2b. Arch Dermatol 1996;132:285-90 (Pubitemid 26085180)
124. Rybojad M, Borradori L, Verola O, et al. Non-AIDS-associated Kaposis sarcoma (classical and endemic African types): treatment with low doses of recombinant interferon-alpha. J Invest Dermatol 1990;95:176S-9S
125. Krueter A, Rasokat H, Klouche M, et al. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposis sarcoma; retrospective analysis of three German centers. Cancer Invest 2005;23:653-9 (Pubitemid 43041711)
126. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007;13:4677-85 (Pubitemid 47294773)
127. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;87:3877-82 (Pubitemid 26129617)
128. Sgadari C, Farber JM, Angiolillo AL, et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997;89:2635-43 (Pubitemid 27172547)
129. Geras-Raaka E, Varma A, Ho H, et al. Human interferon-gamma-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposis sarcoma-associated herpesvirus G protein-coupled receptor. J Exp Med 1998;188:405-8 (Pubitemid 28357769)
130. Little RF, Pluda JM, Wyvill KM, et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 2006;107:4650-7 (Pubitemid 43882610)
131. Little RF, Aleman K, Kumar P, et al. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood 2007;110:4165-71 (Pubitemid 351377778)
132. Chen M, Doherty SD, Hsu S. Innovative uses of thalidomide. Dermatol Clin 2010;28:577-86
133. Fife K, Howard MR, Gracie F, et al. Activity of thalidomide in AIDS-related Kaposis sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998;9:751-5 (Pubitemid 28563172)
134. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposis sarcoma. J Clin Oncol 2000;18:2593-602 (Pubitemid 30432526)
135. Rubegni P, Sbano P, De AG, et al. Thalidomide in the treatment of Kaposis sarcoma. Dermatology 2007;215:240-4
136. Ben Mbarek L, Fardet L, Mebazaa A, et al. A retrospective analysis of thalidomide therapy in non-HIV-related Kaposis sarcoma. Dermatology 2007;215:202-5 (Pubitemid 47378985)
137. List AF. Lenalidomide - the phoenix rises. N Engl J Med 2007;357:2183-6 (Pubitemid 350146115)
138. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39 (Pubitemid 43292566)
139. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposis sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002;20:153-9 (Pubitemid 34032606)
140. Dezube BJ, Sullivan R, Koon HB. Emerging targets and novel strategies in the treatment of AIDS-related Kaposis sarcoma: bidirectional translational science. J Cell Physiol 2006;209:659-62 (Pubitemid 44665684)
141. Brinker BT, Krown SE, Lee JY, et al. Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer 2008;112:1083-8 (Pubitemid 351304593)
142. Toschi E, Sgadari C, Malavasi L, et al. Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome- independent block of angiogenesis and matrix metalloproteinases. Int J Cancer 2011;128:82-93
143. Noy A, von Roenn J, Politsmakher A, et al. Fatal hepatorenal failure and thrombocytopenia with SU5416, a vascular endothelial growth factor Flk-1 receptor inhibitor, in AIDSKaposis sarcoma. AIDS 2007;21:113-15 (Pubitemid 44912548)
144. Levine AM, Tulpule A, Quinn DI, et al. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 2006;24:1712-19 (Pubitemid 46622143)
145. Eckhardt SG, Burris HA, Eckardt JR, et al. A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol 1996;7:491-6 (Pubitemid 26232955)
146. Tulpule A. A phase I study of tecogalan, a novel angiogenesis inhibitor in the treatment of AIDS-related Kaposis sarcoma and solid tumors [abstract]. Blood 1994;84:248a
147. Pluda JM, Shay LE, Foli A, et al. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposis sarcoma. J Natl Cancer Inst 1993;85:1585-92 (Pubitemid 23304687)
148. Schwartsmann G, Sprinz E, Kalakun L, et al. Phase II study of pentosan polysulfate (PPS) in patients with AIDS-related Kaposis sarcoma. Tumori 1996;82:360-3 (Pubitemid 26352955)
149. Noy A, Scadden DT, Lee J, et al. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposis sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol 2005;23:990-8 (Pubitemid 46205948)
150. Tulpule A, Scadden DT, Espina BM, et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposis sarcoma. J Clin Oncol 2000;18:716-23 (Pubitemid 30106601)
151. Dezube BJ, von Roenn JH, Holden-Wiltse J, et al. Fumagillin analog in the treatment of Kaposis sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998;16:1444-9 (Pubitemid 28175764)
152. Aboulafia DM, Norris D, Henry D, et al. 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. Arch Dermatol 2003;139:178-86 (Pubitemid 36216255)
153. Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposis sarcoma. AIDS 2002;16:421-9 (Pubitemid 34165374)
154. Gill PS, Espina BM, Moudgil T, et al. All-trans retinoic acid for the treatment of AIDS-related Kaposis sarcoma: results of a pilot phase II study. Leukemia 1994;8(Suppl 3):S26-32
155. Saiag P, Pavlovic M, Clerici T, et al. Treatment of early AIDS-related Kaposis sarcoma with oral all-trans-retinoic acid: results of a sequential non-randomized phase II trial. Kaposis Sarcoma ANRS Study Group. Agence Nationale de Recherches sur le SIDA. AIDS 1998;12:2169-76 (Pubitemid 28495271)
156. Bower M, Fife K, Landau D, et al. Phase II trial of 13-cis-retinoic acid for poor risk HIV-associated Kaposis sarcoma. Int J STD AIDS 1997;8:518-21 (Pubitemid 27308591)
157. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-96 (Pubitemid 350002890)
158. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367-73 (Pubitemid 46450424)
159. Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib-induced regression of AIDS-related Kaposis sarcoma. J Clin Oncol 2005;23:982-9 (Pubitemid 46202318)
160. Hasskarl J. Sorafenib. Recent Results Cancer Res 2010;184:61-70
161. Ardavanis A, Doufexis D, Kountourakis P, et al. A Kaposis sarcoma complete clinical response after sorafenib administration. Ann Oncol 2008;19:1658-9
162. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22
163. Kedes DH, Ganem D. Sensitivity of Kaposis sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997;99:2082-6 (Pubitemid 27203763)
164. Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposis sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 1996;173:1477-80 (Pubitemid 26286811)
165. Mocroft A, Youle M, Gazzard B, et al. Anti-herpesvirus treatment and risk of Kaposis sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996;10:1101-15
166. Robles R, Lugo D, Gee L, et al. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposis sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:34-8 (Pubitemid 29045467)
167. Morfeldt L, Torssander J. Long-term remission of Kaposis sarcoma following foscarnet treatment in HIV-infected patients. Scand J Infect Dis 1994;26:749-52
168. Casper C. New approaches to the treatment of human herpesvirus 8-associated disease. Rev Med Virol 2008;18:321-9
169. Shaw RN, Arbiser JL, Offermann MK. Valproic acid induces human herpesvirus 8 lytic gene expression in BCBL-1 cells. AIDS 2000;14:899-902 (Pubitemid 30303472)
170. Brown HJ, McBride WH, Zack JA, et al. Prostratin and bortezomib are novel inducers of latent Kaposis sarcoma-associated herpesvirus. Antivir Ther 2005;10:745-51 (Pubitemid 41376854)
171. Lechowicz M, Dittmer DP, Lee JY, et al. Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid. Clin Infect Dis 2009;49:1946-9
172. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60 (Pubitemid 38579481)
173. Sullivan R, Dezube BJ, Koon HB. Signal transduction targets in Kaposis sarcoma. Curr Opin Oncol 2006;18:456-62 (Pubitemid 44199841)
174. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62 (Pubitemid 37329790)
175. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposis sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-23 (Pubitemid 40411498)
176. Sgadari C, Monini P, Barillari G, et al. Use of HIV protease inhibitors to block Kaposis sarcoma and tumour growth. Lancet Oncol 2003;4:537-47 (Pubitemid 38351710)
177. Monini P, Sgadari C, Toschi E, et al. Antitumour effects of antiretroviral therapy. Nat Rev Cancer 2004;4:861-75 (Pubitemid 39472953)
178. Martellotta F, Berretta M, Vaccher E, et al. AIDS-related Kaposis sarcoma: state of the art and therapeutic strategies. Curr HIV Res 2009;7:634-8
179. Sciamanna I, Landriscina M, Pittoggi C, et al. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene 2005;24:3923-31 (Pubitemid 40896404)
180. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002;8:225-32 (Pubitemid 34250099)
181. Pati S, Pelser CB, Dufraine J, et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002;99:3771-9 (Pubitemid 34534550)
182. Gaedicke S, Firat-Geier E, Constantiniu O, et al. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 2002;62:6901-8 (Pubitemid 35424079)
183. Oostendorp RL, Huitema A, Rosing H, et al. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin Cancer Res 2009;15:4228-33
184. Monini P, Sgadari C, Grosso MG, et al. Clinical course of classic Kaposis sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. AIDS 2009;23:534-8
185. Brunner TB, Geiger M, Grabenbauer GG, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008;26:2699-706
186. Ahluwalia MS, Patton C, Stevens G, et al. Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas. J Neurooncol 2011;102:317-21